NCT05717686 - A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

January 7, 2025

Study Completion Date

January 7, 2025

Conditions

Chronic Hepatitis B

Interventions

DRUG

AHB-137 injection

AHB-137 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (9)

New Zealand Clinical Research, Grafton

NYU Langone Health, New York

University of Maryland Baltimore, Baltimore

Chia-Yi Christian Hospital, Chiayi City

American Research Corporation, Houston

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung

E-DA Hospital, Kaohsiung

Stanford Medicine, Redwood City

Queen Mary Hospital, Hong Kong